Table 3. Effect of doxorubicin and ZnO NPs on testicular oxidative stress biomarkers.
Groups | GSH (μmol g–1 wet tissue) | Catalase (unit g–1 wet tissue) | MDA (nmol g–1 wet tissue) |
G1 (Control) | 10.49 ± 0.30b | 7.21 ± 0.18a | 4.88 ± 0.2b |
G2 (ZnO NPs) | 16.89 ± 0.41a | 7.17 ± 0.17a | 4.79 ± 0.16b |
G3 (Doxorubicin) | 6.59 ± 0.18c | 3.23 ± 0.26c | 12.20 ± 0.38a |
G4 (Doxorubicin + ZnO NPs) | 9.83 ± 0.36b | 5.41 ± 0.30b | 4.62 ± 0.55b |